References
- 1. Eikelboom JW, Hirsh J, Spencer FA, et al. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e89S-119S.
- 2. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e637S-68S.
- 3. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (London, England). 2009;373(9678):1849-60.
- 4. Pettersen A a., Arnesen H, Seljeflot I. A brief review on high on-aspirin residual platelet reactivity. Vascul Pharmacol. 2015;67-69:6-9.
- 5. Pedersen SB, Grove EL, Nielsen HL, et al. Evaluation of aspirin response by Multiplate whole blood aggregometry and light transmission aggregometry. Platelets. 2009;20(6):415-20.
- 6. Kovács EG, Katona É, Bereczky Z, et al. Evaluation of laboratory methods routinely used to detect the effect of aspirin against new reference methods. Thromb Res 2014;33(5):811-6.
- 7. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2014.
- 8. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345(25):1809-17.
- 9. Fitzgerald DJ, Maree A. Aspirin and clopidogrel resistance. Hematology Am Soc Hematol Educ Program .2007;(1):114-20.
- 10. Malinin AI, Ong S, Makarov LM, et al. Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors. Int J Clin Pract. 2006;60(8):993-1002.
- 11. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet (London, England). 2006;367(9510):606-17.
- 12. Feher G, Koltai K, Papp E, et al. Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables. Drugs Aging. 2006;23(7):559-67.
- 13. Uzun F, Biyik I, Akturk IF, et al. Antiplatelet resistance and the role of associated variables in stable patients treated with stenting. Postępy w Kardiol interwencyjnej = Adv Interv Cardiol. 2015;11(1):19-25.
- 14. Liu X-F, Cao J, Fan L, et al. Prevalence of and risk factors for aspirin resistance in elderly patients with coronary artery disease. J Geriatr Cardiol. 2013;10(1):21-7.
- 15. Akoglu H, Agbaht K, Piskinpasa S, et al. High frequency of aspirin resistance in patients with nephrotic syndrome. Nephrol Dial Transplant. 2012;27(4):1460-6.
- 16. Kameda S, Sakata T, Kokubo Y, et al. Association of platelet aggregation with lipid levels in the Japanese population: the Suita study. J Atheroscler Thromb. 2011;18(7):560-7.